Chim3 confers survival advantage to CD4+ T cells upon HIV-1 infection by preventing HIV-1 DNA integration and HIV-1-induced G2 cell-cycle delay

Blood

Volumn 115, Issue 20, 2010, Pages 4021-4029

  Porcellini, Simona ^a   Gubinelli, Francesco ^a   Alberici, Luca ^a   Piovani, Bianca Maria ^a   Rizzardi, Gian Paolo ^a   Bovolenta, Chiara ^a  

^a MOLMED S P A   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CHIM3; CUL5; LENTIVIRUS VECTOR; PROTEIN; UNCLASSIFIED DRUG; VIF PROTEIN; VIRUS DNA; VPR PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL CYCLE G2 PHASE; CELL CYCLE REGULATION; CELL SURVIVAL; DNA INTEGRATION; GENE THERAPY; GENETIC ENGINEERING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; VIRUS REPLICATION; CELL CULTURE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOPRECIPITATION; METABOLISM; PHYSIOLOGY; SOUTHERN BLOTTING; VIROLOGY; VIRUS DNA CELL DNA INTERACTION;

BLOTTING, SOUTHERN; CD4-POSITIVE T-LYMPHOCYTES; CELL SURVIVAL; CELLS, CULTURED; DNA, VIRAL; G2 PHASE; GENE THERAPY; HEMATOPOIETIC STEM CELLS; HIV-1; HUMANS; IMMUNOPRECIPITATION; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS INTEGRATION; VIRUS REPLICATION; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77953242929     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-09-243030     Document Type: Article

References (26)

1. von Laer D, Hasselmann S, Hasselmann K. Impact of gene-modified T cells on HIV infection dynamics. J Theor Biol. 2006;238(1):60-77. (Pubitemid 41737797)
2. Vallanti G, Lupo R, Federico M, Mavilio F, Bovolenta C. T lymphocytes transduced with a lentiviral vector expressing F12-vif are protected from HIV-1 infection in an APOBEC3G-independent manner. Mol Ther. 2005;12(4):697-706. (Pubitemid 41350151)
3. Chiu YL, Greene WC. TheAPOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu Rev Immunol. 2008;26:317-353.
4. Malim MH, Emerman M. HIV-1 accessory proteins: ensuring viral survival in a hostile environment. Cell Host Microbe. 2008;3(6):388-398. (Pubitemid 351784365)
5. Goncalves J, Korin Y, Zack J, Gabuzda D. Role of Vif in human immunodeficiency virus type 1 reverse transcription. J Virol. 1996;70(12):8701-8709. (Pubitemid 26378452)
6. Dettenhofer M, Cen S, Carlson BA, Kleiman L, Yu XF. Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription. J Virol. 2000;74(19):8938-8945.
7. Carr JM, Davis AJ, Coolen C, Cheney K, Burrell CJ, Li P. Vif-deficient HIV reverse transcription complexes (RTCs) are subject to structural changes and mutation of RTC-associated reverse transcription products. Virology. 2006;351(1):80-91. (Pubitemid 44056064)
8. Carr JM, Coolen C, Davis AJ, Burrell CJ, Li P. Human immunodeficiency virus 1 (HIV-1) virion infectivity factor (Vif) is part of reverse transcription complexes and acts as an accessory factor for reverse transcription. Virology. 2008;372(1):147-156. (Pubitemid 351215471)
9. Henriet S, Richer D, Bernacchi S, et al. Cooperative and specific binding of Vif to the 5′ region of HIV-1 genomic RNA. J Mol Biol. 2005;354(1):55-72. (Pubitemid 41527214)
10. Henriet S, Sinck L, Bec G, Gorelick RJ, Marquet R, Paillart JC. Vif is a RNAchaperone that could temporally regulate RNAdimerization and the early steps of HIV-1 reverse transcription. Nucleic Acids Res. 2007;35(15):5141-5153. (Pubitemid 47394198)
11. Bernacchi S, Henriet S, Dumas P, Paillart JC, Marquet R. RNA and DNA binding properties of HIV-1 Vif protein: a fluorescence study. J Biol Chem. 2007;282(36):26361-26368. (Pubitemid 47443766)
12. Wang J, Shackelford JM, Casella CR, et al. The Vif accessory protein alters the cell cycle of human immunodeficiency virus type 1 infected cells. Virology. 2007;359(2):243-252. (Pubitemid 46274864)
13. Sakai K, Dimas J, Lenardo MJ. The Vif and Vpr accessory proteins independently cause HIV-1-induced T cell cytopathicity and cell cycle arrest. Proc Natl Acad Sci U S A. 2006;103(9):3369-3374. (Pubitemid 43346476)
14. DeHart JL, Planelles V. Human immunodeficiency virus type 1 Vpr links proteasomal degradation and checkpoint activation. J Virol. 2008;82(3):1066- 1072.
15. Folks T, Benn S, Rabson A, et al. Characterization of a continuous T-cell line susceptible to the cytopathic effects of the acquired immunodeficiency syndrome (AIDS)-associated retrovirus. Proc Natl Acad Sci U S A. 1985;82(13):4539-4543. (Pubitemid 15233156)
16. Clouse KA, Powell D, Washington I, et al. Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol. 1989;142(2):431-438. (Pubitemid 19039959)
17. Porcellini S, Alberici L, Gubinelli F, et al. The F12-Vif derivative Chim3 inhibits HIV-1 replication in CD4+ T lymphocytes and CD34+-derived macrophages by blocking HIV-1 DNA integration. Blood. 2009;113(15):3443-3452.
18. Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997;276(5319):1719-1724. (Pubitemid 27421983)
19. Bour S, Geleziunas R, Wainberg MA. The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection. Microbiol Rev. 1995;59(1):63-93.
20. Chenine AL, Sattentau Q, Moulard M. Selective HIV-1-induced downmodulation of CD4 and coreceptors. Arch Virol. 2000;145(3):455-471. (Pubitemid 30172069)
21. van den Beemd R, Boor PP, van Lochem EG, et al. Flow cytometric analysis of the Vbeta repertoire in healthy controls. Cytometry. 2000;40(4):336-345.
22. Kataropoulou A, Bovolenta C, Belfiore A, et al. Mutational analysis of the HIV-1 auxiliary protein Vif identifies independent domains important for the physical and functional interaction with HIV-1 reverse transcriptase. Nucleic Acids Res. 2009;37(11):3660-3669.
23. Wang GP, Levine BL, Binder GK, et al. Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. Mol Ther. 2009;17(5):844-850.
24. DeHart JL, Bosque A, Harris RS, Planelles V. Human immunodeficiency virus type 1 Vif induces cell cycle delay via recruitment of the same E3 ubiquitin ligase complex that targets APOBEC3 proteins for degradation. J Virol. 2008;82(18):9265-9272.
25. Giri K, Scott RA, Maynard EL. Molecular structure and biochemical properties of the HCCH-Zn2+ site in HIV-1 Vif. Biochemistry. 2009;48(33):7969-7978.
26. Van Duyne R, Pedati C, Guendel I, et al. The utilization of humanized mouse models for the study of human retroviral infections. Retrovirology. 2009;6:76.